ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pembrolizumab and epacadostat work in combination
treating patients with extensive stage small cell lung cancer. Monoclonal antibodies, such as
pembrolizumab, may assist the immune system in recognizing cancer cells leading to
elimination of those cells. Epacadostat may prevent down-regulation of T-cells, which means
it can boost the immune system. Giving pembrolizumab and epacadostat together may work better
than either drug alone in treating extensive stage small cell lung cancer.